42% of surveyed neurologists reported prescribing either SC efgartigimod, rozanolixizumab, or both products within the first two months of commercial availability ("early adopters").
Early adopters reported significantly higher patient shares for originator FcRn blocker IV efgartigimod than non-adopters (11.3% vs 3.6%). Early adopters were more likely than non-adopters to rate themselves as highly familiar with SC efgartigimod (8.1 for adopters, 6.8 for non-adopters on 10-point scale) and to rate both SC FcRn blockers as a significant advance over other agents to treat gMG (7.6 vs 6.4 [SC efgartigimod], 7.1 vs 5.9 [rozanolixizumab]). They were more likely than non-adopters to view more of their patients as candidates for SC efgartigimod (23.4% vs 14.7%).
Early adopters rated market access as significantly better for both SC products than non-adopters (6.8 vs. 4.4; 6.0 vs 4.0). They also were more likely to have a positive perception of launch execution for both SC products (7.7 vs 6.3; 6.7 vs 5.1).
gMG patient load and past month sales representative contact did not significantly differ between early adopters and non-prescribers.